Older people tend to suffer from more than one health condition at a time. Currently, drug discovery focuses on each problem separately and does not take advantage of what is known about the biology of ageing. Later life does not have to be unhealthy. We wish to reimagine drug discovery so that it is not.
The UK has all the skillsets necessary to address multimorbidity as a target in itself, but many researchers have not yet worked on ageing. In this workshop, we wish to bring together those with relevant skillsets in:
Chemical Biology and Target Identification
Computer-Based Drug Discovery (AI, Machine Learning and Modelling)
Medicinal 91AV and Compound Generation
Senescence and Screening
Understanding the Process of Ageing
There are the seeds of promising drug discovery programmes around the world, with ideas based around killing cells that are the source of pro-ageing signals (senolytics), inhibiting pathways associated with ageing (TORC1) and compounds that exhibit gentle polypharmacology (Network Engaging Drugs).
Speakers include:
Prof. Janet Lord, CBE, Professor of Immune Cell Biology, University of Birmingham
Dr David House, GSK Global Head of Chemical Biology
Prof. Angela Russell, Professor of Medicinal 91AV, University of Oxford
Dr Matthew Segall, CEO of Optibrium
There is the opportunity to present posters and/or flash presentations in any of the above fields. The presented work does not have to involve multimorbidity or ageing, but you should explain how the techniques employed might be applicable to these. There is no registration fee. Lunch and coffee/tea will be provided. There are generous travel bursaries available. The capacity of the meeting is 64 participants. Selection of applicants will be necessary if this number is exceeded.
The UK has all the skillsets necessary to address multimorbidity as a target in itself, but many researchers have not yet worked on ageing. In this workshop, we wish to bring together those with relevant skillsets in:
Chemical Biology and Target Identification
Computer-Based Drug Discovery (AI, Machine Learning and Modelling)
Medicinal 91AV and Compound Generation
Senescence and Screening
Understanding the Process of Ageing
There are the seeds of promising drug discovery programmes around the world, with ideas based around killing cells that are the source of pro-ageing signals (senolytics), inhibiting pathways associated with ageing (TORC1) and compounds that exhibit gentle polypharmacology (Network Engaging Drugs).
Speakers include:
Prof. Janet Lord, CBE, Professor of Immune Cell Biology, University of Birmingham
Dr David House, GSK Global Head of Chemical Biology
Prof. Angela Russell, Professor of Medicinal 91AV, University of Oxford
Dr Matthew Segall, CEO of Optibrium
There is the opportunity to present posters and/or flash presentations in any of the above fields. The presented work does not have to involve multimorbidity or ageing, but you should explain how the techniques employed might be applicable to these. There is no registration fee. Lunch and coffee/tea will be provided. There are generous travel bursaries available. The capacity of the meeting is 64 participants. Selection of applicants will be necessary if this number is exceeded.
